Financial executive Norman “Norm” Gretzinger is the co-founder and managing director of EG Capital in New York City. In this capacity, Norm Gretzinger played a central role in the Series B financing of OncoPep, an early stage immunotherapeutics company involved in cancer vaccine research.
Therapeutic cancer vaccines developed by OncoPep rely on the effective response of the immune system to cancerous cells. Instead of preventing diseases in the future, therapeutic cancer vaccines actually treat a disease that exists in the body currently. As such, immunotherapeutics has emerged as one of the most exciting new areas of cancer research.
OncoPep has developed a novel cancer vaccine known as PVX-410, which uses a peptide-signaling system to detect cell-specific antigens located on multiple myeloma (MM) cells. Once the immune system is prompted to recognize these antigens, it carries out its normal function of destroying harmful cells in the body. When administered to patients with the precursor disease smoldering multiple myeloma (SMM), PVX-410 displays potent therapeutic activity. As such, the vaccine is currently involved in clinical trials at various cancer centers, including Massachusetts General Hospital in Boston and Winship Cancer Institute of Emory University.
Therapeutic cancer vaccines developed by OncoPep rely on the effective response of the immune system to cancerous cells. Instead of preventing diseases in the future, therapeutic cancer vaccines actually treat a disease that exists in the body currently. As such, immunotherapeutics has emerged as one of the most exciting new areas of cancer research.
OncoPep has developed a novel cancer vaccine known as PVX-410, which uses a peptide-signaling system to detect cell-specific antigens located on multiple myeloma (MM) cells. Once the immune system is prompted to recognize these antigens, it carries out its normal function of destroying harmful cells in the body. When administered to patients with the precursor disease smoldering multiple myeloma (SMM), PVX-410 displays potent therapeutic activity. As such, the vaccine is currently involved in clinical trials at various cancer centers, including Massachusetts General Hospital in Boston and Winship Cancer Institute of Emory University.